10-Q: DT Cloud Faces Going Concern Amid Redemptions

DT Cloud Acquisition Corporation reports significant redemptions and liquidity challenges, raising substantial doubt about its ability to continue as a going concern.

Summary

• DT Cloud Acquisition Corporation (DYCQ) is a blank check company formed to effect a business combination, with its activities primarily focused on evaluating potential targets.
• The company entered into a definitive business combination agreement with Maius Pharmaceutical Co., Ltd. (Maius) on October 22, 2024, with an aggregate consideration of $250,000,000 in newly issued Pubco ordinary shares.
• As of June 30, 2025, cash and investments held in the trust account significantly decreased to $9,058,036 from $72,345,071 at December 31, 2024, primarily due to substantial shareholder redemptions.
• Shareholder redemptions totaled 6,067,585 shares across three events in March, April, and May 2025, at prices ranging from approximately $10.61 to $10.79 per share, aggregating over $65 million.
• The company's cash balance outside the trust account was $0 as of June 30, 2025, down from $152,021 at December 31, 2024.
• Net income for the six months ended June 30, 2025, was $686,742, a decrease from $872,741 for the same period in 2024.
• The company incurred $598,393 in cash used in operating activities for the six months ended June 30, 2025, an increase from $524,310 in the prior year period.
• Promissory notes totaling $545,975 were issued to Maius in May and June 2025, which are unsecured, non-interest-bearing, and mature upon the closing of a business combination.
• The company has extended its business combination period multiple times, with the current deadline extended to August 23, 2026, contingent on the Sponsor depositing additional funds.
• As of the filing date (August 8, 2025), the required July 2025 extension fee of $60,000 had not been deposited into the Trust Account, raising substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the explicit going concern warning, massive shareholder redemptions, critically low cash balance, and uncertainty surrounding the business combination and future financing. The company's ability to survive is in question.

Positives

• The company has a definitive business combination agreement in place with Maius Pharmaceutical Co., Ltd., indicating progress towards its primary objective.
• The Sponsor and its affiliates have historically provided loans and administrative services to support the company's operations and extensions.

Negatives

• Significant shareholder redemptions have drastically reduced the funds available in the trust account, from $72.3 million to $9.1 million.
• The company's cash balance outside the trust account is $0 as of June 30, 2025, indicating severe liquidity constraints for ongoing operations.
• Net income decreased for both the three and six months ended June 30, 2025, compared to the prior year periods.
• Cash used in operating activities increased, reflecting higher cash burn.
• The company has identified material weaknesses in its internal control over financial reporting, specifically inadequate segregation of duties and insufficient written policies and procedures.
• The required July 2025 extension fee of $60,000 was not deposited as of the filing date, directly leading to a going concern warning.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to liquidity issues and the uncertainty of completing the business combination by the extended deadline.
• The completion of the business combination is subject to numerous conditions, including shareholder and regulatory approvals (e.g., CSRC), which may not be obtained or could be delayed.
• There is no assurance that the contemplated PIPE financing of at least $10,000,000 will be completed, which could impact the business combination's attractiveness and feasibility.
• The business combination may not qualify as a Section 351 Exchange for U.S. federal income tax purposes, potentially resulting in taxable gain for U.S. holders.
• The Sponsor and management have interests that may conflict with those of public shareholders, as their investment would be lost if the business combination is not completed.
• Geopolitical instability (Russia-Ukraine, Israel-Hamas conflicts) and economic uncertainties could adversely affect the global economy, capital markets, and the target business.
• Political and economic tensions between the United States and China may affect the target business, Maius, which is based in China.
• Dependence on U.S. and multi-national financial institutions for banking services, with deposits exceeding insured limits, poses a risk in case of institutional failure.

Future Outlook

The company's future outlook is highly uncertain, primarily dependent on its ability to complete the business combination with Maius Pharmaceutical. The company intends to continue seeking to complete the business combination before the mandatory liquidation date of August 23, 2026 (if all extensions are made). However, the failure to deposit the July 2025 extension fee and the lack of secured PIPE financing raise significant doubts about its ability to meet these objectives and continue as a going concern.

Management Comments

• Management has determined that if the company is unsuccessful in consummating an Initial Business Combination within the prescribed period of time (subject to the Amended Extension Payment is made as required for each monthly extension), the requirement that the company cease all operations, redeem the Public Shares and thereafter liquidate and dissolve raises substantial doubt about the company’s ability to continue as a going concern within one year after the date that the financial statements are issued.
• As of the date that these unaudited financial statements were issued, the company has not deposited the July 2025 required extension fee into the Trust Account.

Industry Context

The company operates as a Special Purpose Acquisition Company (SPAC), a sector that has experienced increased scrutiny and redemptions in recent periods. The significant redemptions observed in this filing are consistent with broader market trends where SPACs face challenges in retaining capital and completing business combinations. The target industry, pharmaceuticals, is capital-intensive and subject to extensive regulatory oversight, adding complexity to the proposed merger. Geopolitical tensions, particularly between the U.S. and China, introduce additional uncertainty for cross-border transactions involving Chinese entities like Maius.

Comparison to Industry Standards

• The high redemption rate (over 87% of public shares redeemed) is significantly above the average redemption rates seen in the SPAC market, which typically range from 50-70% in challenging environments, indicating a strong lack of investor confidence in the proposed business combination or the SPAC structure itself.
• The trust account balance of $9.06 million is substantially lower than many SPACs at this stage of their lifecycle, making it challenging to meet the Nasdaq 80% fair market value rule for a business combination, especially for a target valued at $250 million.
• The company's cash balance of $0 outside the trust account is critically low compared to industry peers, many of whom maintain sufficient working capital to cover operational expenses and extension fees without immediate reliance on sponsor loans.
• The explicit 'going concern' disclosure is a severe indicator, often seen in SPACs nearing their liquidation deadline without a viable path to a business combination or sufficient funds to extend.
• The reliance on sponsor loans for extensions and working capital, coupled with the failure to deposit the latest extension fee, highlights a more precarious financial position than many SPACs that successfully complete extensions.

Corporate Governance

Legal Proceedings

• No legal proceedings were reported in the filing.

Related Party Transactions

• The Sponsor (DT Cloud Capital Corp.) was issued 1,725,000 founder shares for $25,000 in July 2022.
• The Sponsor purchased 234,500 Private Placement Units for $10.00 per unit, generating $2,345,000 gross proceeds, simultaneously with the IPO.
• As of June 30, 2025, the company had $368,127 due to the Sponsor for temporary advances and unpaid service fees, which are unsecured, interest-free, and have no fixed repayment terms.
• An affiliate of the Sponsor provides administrative services for $10,000 per month, with $160,000 in unpaid fees as of June 30, 2025.
• The Sponsor or its affiliates may provide Working Capital Loans, up to $300,000 of which may be convertible into private units upon business combination. No outstanding balance as of June 30, 2025.
• The Sponsor is obligated to provide non-interest bearing Extension Loans for the sole purpose of extending the business combination deadline.
• The company issued three unsecured promissory notes totaling $545,975 to Maius (the target company) in May and June 2025, which do not bear interest and mature upon closing of a business combination.

Stakeholder Impact

• Shareholders: Those who redeemed received their pro rata share of the trust account, while remaining public shareholders face significant dilution risk from potential PIPE financing and uncertainty regarding the business combination's completion and the company's going concern status. Founder shares and private units held by the Sponsor are at risk of becoming worthless if the business combination fails.
• Employees: As a blank check company, there are no operational employees beyond management, so direct impact is minimal, but the uncertainty affects future employment prospects post-business combination.
• Creditors: The Sponsor has agreed to be liable for certain claims by vendors or target businesses if the trust account falls below $10.05 per share, providing some protection, but the company's overall liquidity issues could impact other creditors.
• Management: Officers and directors have significant personal and financial interests tied to the completion of the business combination, as their founder shares and private units would expire worthless otherwise.

Next Steps

• The company needs to deposit the July 2025 extension fee of $60,000 into the Trust Account to extend the business combination period to August 23, 2025.
• The company must continue efforts to secure the PIPE Investment of at least $10,000,000 from third-party investors.
• The company must work towards satisfying the remaining conditions for the business combination, including obtaining necessary shareholder and regulatory approvals (e.g., CSRC).
• Management needs to address the identified material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

The company faces an existential threat, explicitly stating 'substantial doubt about its ability to continue as a going concern' due to critically low cash and the failure to deposit a required extension fee. This, combined with massive shareholder redemptions (over 87% of public shares), a significantly depleted trust account, and the uncertainty of securing crucial PIPE financing for its proposed business combination with Maius, paints a dire picture. The identified material weaknesses in internal controls further compound the risks. Given these severe liquidity issues, operational uncertainties, and the high probability of liquidation, the stock carries extreme risk, making a 'strong sell' recommendation appropriate for any remaining public shareholders.

Keywords

SPAC, Business Combination, Maius Pharmaceutical, Redemptions, Going Concern, Trust Account, PIPE Financing, SEC Filing, Quarterly Report, DYCQ, Acquisition, Biotechnology, Pharmaceutical